Kukreja N - Search Results

1

Revascularization in the high-risk patient: multivessel disease.

Onuma Y, Daemen J, Kukreja N, Serruys P. Onuma Y, et al. Among authors: kukreja n. Minerva Cardioangiol. 2007 Oct;55(5):579-92. Minerva Cardioangiol. 2007. PMID: 17912164 Review.

2

Invasive imaging techniques for the assessment of vulnerable plaque.

Kukreja N, Garcia-Garcia HM, Serruys PW. Kukreja N, et al. Minerva Cardioangiol. 2006 Oct;54(5):603-17. Minerva Cardioangiol. 2006. PMID: 17019397 Review.

3

Sirolimus-eluting stents, bare metal stents or coronary artery bypass grafting for patients with multivessel disease including involvement of the proximal left anterior descending artery: analysis of the Arterial Revascularization Therapies study part 2 (ARTS-II).

Kukreja N, Serruys PW, De Bruyne B, Colombo A, Macaya C, Richardt G, Fajadet J, Hamm C, Goedhart D, Macours N, Stoll HP; ARTS-II Investigators. Kukreja N, et al. Heart. 2009 Jul;95(13):1061-6. doi: 10.1136/hrt.2008.157735. Epub 2009 Mar 19. Heart. 2009. PMID: 19304671 Clinical Trial.

4

The future of drug-eluting stents.

Kukreja N, Onuma Y, Daemen J, Serruys PW. Kukreja N, et al. Pharmacol Res. 2008 Mar;57(3):171-80. doi: 10.1016/j.phrs.2008.01.012. Epub 2008 Feb 2. Pharmacol Res. 2008. PMID: 18339557 Review.

5

Four-year clinical follow-up of the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital registry.

Daemen J, Kukreja N, van Twisk PH, Onuma Y, de Jaegere PP, van Domburg R, Serruys PW. Daemen J, et al. Among authors: kukreja n. Am J Cardiol. 2008 Apr 15;101(8):1105-11. doi: 10.1016/j.amjcard.2007.11.074. Epub 2008 Feb 20. Am J Cardiol. 2008. PMID: 18394442

6

Four-year safety and efficacy of the unrestricted use of sirolimus- and paclitaxel-eluting stents in coronary artery bypass grafts.

van Twisk PH, Daemen J, Kukreja N, van Domburg RT, Serruys PW. van Twisk PH, et al. Among authors: kukreja n. EuroIntervention. 2008 Nov;4(3):311-7. doi: 10.4244/eijv4i3a57. EuroIntervention. 2008. PMID: 19110803

7

Three-year survival following multivessel percutaneous coronary intervention with bare-metal or drug-eluting stents in unselected patients.

Kukreja N, Onuma Y, Garcia-Garcia HM, Daemen J, van Domburg R, Serruys PW; Interventional Cardiologists of the Thoraxcenter (2000-5). Kukreja N, et al. Am J Cardiol. 2009 Jan 15;103(2):203-11. doi: 10.1016/j.amjcard.2008.08.068. Epub 2008 Nov 19. Am J Cardiol. 2009. PMID: 19121437

8

The relative safety and efficacy of bare-metal and drug-eluting stents in low and high-risk patient subsets. An epidemiological analysis of three sequential cohorts of consecutive all comers (n = 6129).

Daemen J, van Twisk PH, Kukreja N, van Domburg RT, Boersma E, de Jaegere P, Serruys PW. Daemen J, et al. Among authors: kukreja n. EuroIntervention. 2009 Jan;4(4):464-74. doi: 10.4244/eijv4i4a80. EuroIntervention. 2009. PMID: 19284068

9

Xience V everolimus-eluting coronary stent.

Kukreja N, Onuma Y, Serruys PW. Kukreja N, et al. Expert Rev Med Devices. 2009 May;6(3):219-29. doi: 10.1586/erd.09.1. Expert Rev Med Devices. 2009. PMID: 19419279 Review.

10

The risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents.

Kukreja N, Onuma Y, Garcia-Garcia HM, Daemen J, van Domburg R, Serruys PW; Interventional Cardiologists of the Thoraxcenter (2000 to 2005). Kukreja N, et al. JACC Cardiovasc Interv. 2009 Jun;2(6):534-41. doi: 10.1016/j.jcin.2009.04.003. JACC Cardiovasc Interv. 2009. PMID: 19539258 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

124 results

Search Page

Filters